iBio FY2025 revenue $0.4M, cash $8.8M; advances obesity pipeline with IBIO-610 fat loss data

iBio, Inc.

Revenue $0.4M (up $0.2M YoY); R&D expense $8.3M (+$3.1M); G&A $10.7M (-$1.0M).
Cash $8.8M at June 30; raised $6.2M warrant inducement; closed $50M public offering (potential +$50M on warrant exercise).
IBIO-610 (activin E) showed 26% fat mass reduction with no lean mass loss in mice; NHP study initiated.
IBIO-600 (anti-myostatin) NHP PK data demonstrated extended half-life and dose-dependent muscle growth.
Collaboration with AstralBio yielded amylin receptor antibody reducing acute food intake 60% in obese mice.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.